Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 559

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 559
---
) entered into with other Persons in the ordinary course of business under which there exists no material default; (iv) pledges or deposits
to secure obligations pursuant to workers’ compensation Laws or similar legislation or to secure public or statutory obligations; (v) pledges and deposits to secure the performance of bids, trade contracts, leases, surety and appeal bonds,
performance bonds and other obligations of a similar nature, in each case in the ordinary course of business; (vi) easements, covenants, encumbrances and rights of way of record, in each case that do not, and are not reasonably likely to,
adversely affect in any material respect the current use or occupancy of the applicable property owned, leased, used or held for use by the Company; (vii) zoning, building and other similar codes or restrictions that are not violated in any
material respect by the current use or occupancy by the Company of the real property subject thereto; (viii) statutory, common law or contractual Liens of landlords under real property leases; and
(ix) non-exclusive licenses, sub-licenses or other rights to Company Intellectual Property.

(yyy) “Person” means any individual or Entity.

(zzz) “Pre-ClosingPeriod” means the period commencing with the execution and
delivery of this Agreement and continuing until the earlier to occur of (i) the termination of this Agreement pursuant to and (ii) the Closing Date.

(aaaa) “Pre-ClosingTax Period” means any taxable year or period that ends on or
before the Closing Date, and the portion of any Straddle Period ending on and including the Closing Date.

A-12

(bbbb) “PRECISION-1Clinical Trial”
means the Phase 2 multi-center open-label basket Clinical Trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes conducted by or
on behalf of the Company and Seller.

(cccc) “Purchased Shares” means all of the issued and outstanding shares of Company
Capital Stock (all of which are owned beneficially and of record by Seller).

(dddd) “Purchaser Material Adverse Effect”
means any Effect that, individually or taken together with all other Effects, prevents or could reasonably be expected to prevent Purchaser from consummating the Stock Purchase or the ability of Purchaser to perform its covenants and obligations
pursuant to this Agreement on or prior to the